There are currently 58 active clinical trials seeking participants for Atopic Dermatitis research studies. The states with the highest number of trials for Atopic Dermatitis participants are California, Florida, Texas and Ontario.
Topical ENS-002 for Atopic Dermatitis in Adults
NCT06469385
Recruiting
The goal of this study is to determine the safety and effects of ENS-002, a live biotherapeutic product (LBP) consisting of commensal, clonal, non-pathogenic bacteria in participants with atopic dermatitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Encore Medical Research, Hollywood, Florida +2 locations
Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema
Register for Updates
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in pediatric participants with moderate to severe AD who are candidates for systemic therapy. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug... Read More
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
02/18/2025
Locations: Applied Research Center Of Arkansas /ID# 268547, Little Rock, Arkansas +87 locations
Conditions: Atopic Dermatitis
Register for Updates
Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism
NCT04455906
Recruiting
This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.
Gender:
ALL
Ages:
Between 6 years and 65 years
Trial Updated:
02/15/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Atopic Dermatitis
Register for Updates
A Study of Barzolvolimab in Patients With Atopic Dermatitis
NCT06727552
Recruiting
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Cahaba Dermatology & Skin Health Center, Birmingham, Alabama +5 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05882877
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
02/12/2025
Locations: Cahaba Dermatology and Skin Health Center, Birmingham, Alabama +514 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
NCT06389136
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD. Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This stud... Read More
Gender:
ALL
Ages:
Between 18 years and 63 years
Trial Updated:
02/12/2025
Locations: Clinical Trials Institute - Northwest Arkansas /ID# 267290, Fayetteville, Arkansas +82 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05559359
Recruiting
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD).
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
02/11/2025
Locations: Clinical Research Center of Alabama, Birmingham, Alabama +98 locations
Conditions: Atopic Dermatitis, Eczema
Register for Updates
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
NCT06238817
Recruiting
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2025
Locations: Lynn Institute of the Ozarks, Little Rock, Arkansas +99 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
NCT06718101
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to evaluate the clinical efficacy and safety of single therapies and/or combination therapies for moderate to severe AD through multiple substudies. This study will consist of multiple sub-studies, Sub-Study 1 will have a randomized, placebo controlled period 1 followed by a lutikizumab treatment period 2 enrolling 80 participants at a 1 to 1 ratio. In Sub-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2025
Locations: Research Associates of South Florida /ID# 272549, Miami, Florida +2 locations
Conditions: Atopic Dermatitis
Register for Updates
The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.
NCT05696392
Recruiting
The purpose of the study is to evaluate the effect of ruxolitinib cream on sleep disturbances with participants with Atopic Dermatitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2025
Locations: First Oc Dermatology, Fountain Valley, California +29 locations
Conditions: Atopic Dermatitis
Register for Updates
Seal, Stopping Eczema and Allergy Study
NCT03742414
Recruiting
This is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (AD or eczema) by 12 weeks of age. The aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone propionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
Gender:
ALL
Ages:
Between 1 week and 12 weeks
Trial Updated:
02/06/2025
Locations: Sean N. Parker Center for Allergy & Asthma Research at Stanford University, Palo Alto, California +4 locations
Conditions: Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
Register for Updates
Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
NCT05436535
Recruiting
This is a multi-center, longitudinal study which will characterize the gene expression profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic dermatitis (AD) and will determine changes in these expression patterns and endotypes in response to standard-of-care treatment. Participants will complete up to ten scheduled study visits with assessment of topical steroid response and dupilumab response (if uncontrolled with topical steroids). Skin samples will be collected a... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
02/04/2025
Locations: University of California, San Diego: Dermatology Clinical Trials Unit, La Jolla, California +9 locations
Conditions: Atopic Dermatitis
Register for Updates